Condition
Monomorphic Post-Transplant Lymphoproliferative Disorder
Total Trials
1
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Rituximab
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 1 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (1)
Research Network
Common Treatments
- Rituximab1
- Allogeneic Lmp1lmp2specific Cytotoxic Tlymphocytes1
Active Sponsors
- National Cancer Institute (NCI)1
- Children's Oncology Group1
Top Investigators
Children's Oncology Group
Related Conditions
- Refractory Polymorphic Posttransplant Lymphoproliferative Disorder1
- Ebvrelated Posttransplant Lymphoproliferative Disorder1
- Recurrent Monomorphic Posttransplant Lymphoproliferative Disorder1
- Recurrent Polymorphic Posttransplant Lymphoproliferative Disorder1
- Refractory Monomorphic Posttransplant Lymphoproliferative Disorder1